IFN‐γ promotes transendothelial migration of CD4+ T cells across the blood–brain barrier

SA Sonar, S Shaikh, N Joshi, AN Atre… - Immunology and cell …, 2017 - Wiley Online Library
Transendothelial migration (TEM) of Th1 and Th17 cells across the blood–brain barrier
(BBB) has a critical role in the development of experimental autoimmune encephalomyelitis …

Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells

HK Gan, M van den Bent, AB Lassman… - Nature reviews Clinical …, 2017 - nature.com
Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few
available therapeutic options. This lack of effective treatments has been linked to diverse …

[HTML][HTML] Molecular targeted therapy: a new avenue in glioblastoma treatment

O El Atat, R Naser, M Abdelkhalek… - Oncology …, 2023 - spandidos-publications.com
Glioblastoma, also referred to as glioblastoma multiforme (GBM), is grade IV astrocytoma
characterized by being fast‑growing and the most aggressive brain tumor. In adults, it is the …

Nanoparticles for radiooncology: Mission, vision, challenges

LA Kunz-Schughart, A Dubrovska, C Peitzsch, A Ewe… - Biomaterials, 2017 - Elsevier
Cancer is one of the leading non-communicable diseases with highest mortality rates
worldwide. About half of all cancer patients receive radiation treatment in the course of their …

Pathway inhibition: emerging molecular targets for treating glioblastoma

W Wick, M Weller, M Weiler, T Batchelor… - Neuro …, 2011 - academic.oup.com
Insights into the molecular pathogenesis of glioblastoma have not yet resulted in relevant
clinical improvement. With standard therapy, which consists of surgical resection with …

Programmed cell death pathways and current antitumor targets

ML Tan, JP Ooi, N Ismail, AIH Moad… - Pharmaceutical …, 2009 - Springer
Apoptosis and autophagic cell deaths are programmed cell deaths and they play essential
roles in cell survival, growth and development and tumorigenesis. The huge increase of …

PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis

F Han, R Hu, H Yang, J Liu, J Sui, X Xiang… - OncoTargets and …, 2016 - Taylor & Francis
Background We conducted this meta-analysis based on eligible trials to investigate the
relationship between phosphatase and tensin homolog (PTEN) genetic mutation and glioma …

New approaches to glioblastoma

M Khasraw, Y Fujita, C Lee-Chang… - Annual review of …, 2022 - annualreviews.org
Faced with unique immunobiology and marked heterogeneity, treatment strategies for
glioblastoma require therapeutic approaches that diverge from conventional oncological …

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

B Geoerger, D Hargrave, F Thomas, A Ndiaye… - Neuro …, 2010 - academic.oup.com
This multicenter phase I study aimed to establish the recommended dose (RD) of the
epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with …

[HTML][HTML] Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity

SJ Han, I Yang, T Tihan, MD Prados… - Journal of neuro-oncology, 2010 - Springer
This report presents the historical experience, clinical presentation, treatment, prognosis,
and pathogenesis of gliosarcoma described to date in the English literature. PubMed query …